ETNB Company Profile and Key Details

The stock is currently within 5% of its 52-week high $4.16 and $15.06. With a market capitalization of about $2.20 billion, 89bio, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.26). Key stats such as the average daily volume over the past year has been around 5.39 million shares, trading with heavier-than-usual volume. Headquartered in San Francisco, CA, 89bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rohan Palekar, the company employs approximately 93 people and listed since November 11, 2019. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.

Short-term trend indicators are bearishly aligned (SMA20 0.17%, SMA50 19.62%, SMA200 52.21%). The stock’s 14-day RSI is 76.94 (overbought), while the ATR of 0.16 points to moderate volatility. The stock remains hovering near 52-week lows, trading -1.46% below its high and over 256.73% above its low.

89bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.85. This means the shares are trading above this model’s fair value.

89bio, Inc. generated EPS of -$3.61 over the past year. Five-year average earnings growth is 32.21%. Wall Street analysts project EPS growth of 15.21% annually over the next five years. The latest quarter delivered EPS of -$1.39. The next quarter is forecast at -$0.50. Next year's EPS is expected at -$23.95. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $11.00. The high target offers 115.63% upside. The low target suggests -25.88% downside. The mean target is $20.42. This offers 37.6% upside. 89bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 178.0%. The prior quarter beat by 44.9%. Over the last six quarters, Apple has recorded several small beats. These include -14.29% in August 05, 2024.

89bio, Inc. has 148.31 million shares outstanding. The public float is 103.73 million shares, elevated short interest at 14.73% of float. This equals 15.79 million shares. The short ratio is 11.3 days. Institutional investors hold 112.48% of the float. Insiders own 0.54%. RA CAPITAL MANAGEMENT, L.P. holds 19.55 million shares, Shah Rajeev M. has 7.78 million shares and Longitude Capital Partners III, LLC has 2.60 million shares.

89bio, Inc. (NASDAQ:ETNB) shares are up 89.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows 89bio, Inc. trading at a premium to the broader market with a P/E of -5.2. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $33.26, suggesting 124.12% upside. Our AI forecast model points to short-term strength (10.58% over two weeks), a medium-term rise (128.1% over three months), and a longer-term gain (179.31% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that 89bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.58%, with price expected at $16.41 by November 12, 2025, within a range of $14.09 to $18.78 3-Month Outlook: Projected rise of 128.1%, reaching $33.85 by January 27, 2026, with a range of $33.54 to $34.38. 1-Year Outlook: Projected gain of 179.31%, with price at $41.45 by October 29, 2026, within a range of $35.54 to $55.57.

89bio, Inc. trades at a P/E ratio of -5.2, slightly below the S&P 500 average, with a price-to-sales ratio of 104798.07 and a price-to-book ratio of 4.49 trading at moderately above to book value. The P/FCF stands at -5.01, also above market averages.